I agree that this site is using cookies. You can find further informations here.
X
Viljoen, Adie
99  results:
Search for persons X
?
1

SGLT2 Inhibitors – The New Standard of Care for Cardiovascu..:

Seidu, Samuel ; Alabraba, Vicki ; Davies, Sarah...
Diabetes Therapy.  15 (2024)  5 - p. 1099-1124 , 2024
Link: https://doi.org/10.1007/..
 
?
2

The Road towards Triple Agonists: Glucagon-Like Peptide 1, ..:

Jakubowska, Agnieszka ; Roux, Carel W. le ; Viljoen, Adie
Endocrinology and Metabolism.  39 (2024)  1 - p. 12-22 , 2024
Link: https://doi.org/10.3803/..
 
?
3

Time to Reach Glycaemic and Body Weight Loss Thresholds wit..:

Viljoen, Adie ; Pantalone, Kevin M. ; Galindo, Rodolfo J....
Diabetes Therapy.  14 (2023)  5 - p. 925-936 , 2023
Link: https://doi.org/10.1007/..
 
?
4

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 D..:

Viljoen, Adie ; Bain, Stephen C.
Endocrinology and Metabolism.  38 (2023)  1 - p. 25-33 , 2023
Link: https://doi.org/10.3803/..
 
?
5

The long-term cost-effectiveness of once-weekly semaglutide..:

Viljoen, Adie ; Chubb, Barrie ; Malkin, Samuel J. P....
The European Journal of Health Economics.  24 (2022)  6 - p. 895-907 , 2022
Link: https://doi.org/10.1007/..
 
?
6

Meeting the Challenge of Virtual Diabetes Care: A Consensus..:

Evans, Marc ; Morgan, Angharad R. ; Bain, Stephen C....
Diabetes Therapy.  13 (2022)  2 - p. 225-240 , 2022
Link: https://doi.org/10.1007/..
 
?
7

The Place and Value of Sodium-Glucose Cotransporter 2 Inhib..:

Wilding, John P. H. ; Evans, Marc ; Fernando, Kevin...
Diabetes Therapy.  13 (2022)  5 - p. 847-872 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Comparative efficacy of non-statin lipid-lowering therapies..:

Burnett, Heather ; Fahrbach, Kyle ; Cichewicz, Allie...
Current Medical Research and Opinion.  38 (2022)  5 - p. 777-784 , 2022
Link: https://doi.org/10.1080/..
 
?
9

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Ad..:

Davies, Melanie ; Færch, Louise ; Jeppesen, Ole K...
Journal of the Endocrine Society.  5 (2021)  Supplement_1 - p. A10-A11 , 2021
Link: https://doi.org/10.1210/..
 
?
10

An indirect treatment comparison of the efficacy of semaglu..:

Pratley, Richard E. ; Catarig, Andrei‐Mircea ; Lingvay, Ildiko...
Diabetes, Obesity and Metabolism.  23 (2021)  11 - p. 2513-2520 , 2021
Link: https://doi.org/10.1111/..
 
?
11

Elevated Lipoprotein(a): Background, Current Insights and F..:

Handle, Ahmed ; Viljoen, Adie ; Wierzbicki, Anthony S
Vascular Health and Risk Management.  17 (2021)  - p. 527-542 , 2021
Link: https://doi.org/10.2147/..
 
?
12

Semaglutide 2·4 mg once a week in adults with overweight or..:

Davies, Melanie ; Færch, Louise ; Jeppesen, Ole K...
The Lancet.  397 (2021)  10278 - p. 971-984 , 2021
Link: https://doi.org/10.1016/..
 
?
13

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progres..:

Wheeler, David C. ; James, June ; Patel, Dipesh...
Diabetes Therapy.  11 (2020)  12 - p. 2757-2774 , 2020
Link: https://doi.org/10.1007/..
 
?
14

61 - Comparable Efficacy of Once-Weekly Subcutaneous Semagl..:

Jain, Akshay ; Warren, Mark L. ; Hindsberger, Charlotte...
Canadian Journal of Diabetes.  44 (2020)  7 - p. S26 , 2020
Link: https://doi.org/10.1016/..
 
?
15

Corrigendum to "HEART UK consensus statement on Lipoprotein..:

Cegla, Jaimini ; Neely, R. Dermot G. ; France, Michael...
Atherosclerosis.  296 (2020)  - p. 48 , 2020
Link: https://doi.org/10.1016/..
 
1-15